<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<style type="text/css">
.txt { white-space:nowrap; }
#f0 { font-family:sans-serif; font-weight:normal; font-style:normal; }
#f1 { font-family:sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff0; src: url("0.ttf"); }
#f2 { font-family:ff0,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff1; src: url("1.ttf"); }
#f3 { font-family:ff1,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff2; src: url("2.ttf"); }
#f4 { font-family:ff2,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff3; src: url("3.ttf"); }
#f5 { font-family:ff3,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff4; src: url("4.ttf"); }
#f6 { font-family:ff4,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff5; src: url("5.ttf"); }
#f7 { font-family:ff5,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff6; src: url("6.ttf"); }
#f8 { font-family:ff6,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff7; src: url("7.ttf"); }
#f9 { font-family:ff7,sans-serif; font-weight:normal; font-style:normal; }
#f10 { font-family:sans-serif; font-weight:bold; font-style:normal; }
@font-face { font-family: ff8; src: url("8.ttf"); }
#f11 { font-family:ff8,sans-serif; font-weight:normal; font-style:normal; }
</style>
</head>
<body>
<img id="background" style="position:absolute; left:0px; top:0px;" width="595" height="841" src="page1.png">
<div class="txt" style="position:absolute; left:38px; top:107px;"><span id="f3" style="font-size:27px;vertical-align:baseline;color:rgba(0,0,0,1);">한미약품</span><span id="f4" style="font-size:21px;vertical-align:baseline;color:rgba(0,0,0,1);">(128940)</span></div>
<div class="txt" style="position:absolute; left:412px; top:30px;"><span id="f3" style="font-size:18px;vertical-align:baseline;color:rgba(0,0,0,1);">기업 </span><span id="f10" style="font-size:14px;vertical-align:baseline;color:rgba(0,0,0,1);">Note</span></div>
<div class="txt" style="position:absolute; left:412px; top:59px;"><span id="f10" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">2019. 7. 4</span></div>
<div class="txt" style="position:absolute; left:38px; top:172px;"><span id="f3" style="font-size:14px;vertical-align:baseline;color:rgba(0,0,0,1);">글로벌 신약개발의 높은 벽을 이제는 인정해야</span></div>
<div class="txt" style="position:absolute; left:412px; top:174px;"><span id="f3" style="font-size:18px;vertical-align:baseline;color:rgba(0,0,0,1);">중립</span><span id="f4" style="font-size:18px;vertical-align:baseline;color:rgba(0,0,0,1);">(</span><span id="f3" style="font-size:18px;vertical-align:baseline;color:rgba(0,0,0,1);">하향</span><span id="f4" style="font-size:18px;vertical-align:baseline;color:rgba(0,0,0,1);">)</span></div>
<div class="txt" style="position:absolute; left:38px; top:207px;"><span id="f5" style="font-size:12px;vertical-align:baseline;color:rgba(85,146,206,1);">또 다시 뼈 아픈 파이프라인 반환</span></div>
<div class="txt" style="position:absolute; left:38px; top:225px;"><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">전일 한미약품은 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">2015</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">년 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">Janssen</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">에 기술수출한 비만 및 당뇨치료제</span></div>
<div class="txt" style="position:absolute; left:38px; top:240px;"><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">HM12525A</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">의 권리반환 사실을 공시했다</span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">. </span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">최근 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">Janssen</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">이 진행한 두 건의 비만</span></div>
<div class="txt" style="position:absolute; left:38px; top:256px;"><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">환자 대상 임상 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">2</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">상에서 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">1</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">차 평가지표인 체중감소 목표치는 도달했으나 당뇨를</span></div>
<div class="txt" style="position:absolute; left:38px; top:273px;"><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">동반한 비만환자에서 혈당 조절이 내부기준에 미치지 못했기 때문이다</span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">.</span></div>
<div class="txt" style="position:absolute; left:38px; top:289px;"><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">HM12525A</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">는 약효지속기간을 늘린 랩스커버리 기술을 적용해 체중감소와 혈당</span></div>
<div class="txt" style="position:absolute; left:38px; top:304px;"><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">조절을 동시에 도와주는 비만 및 당뇨 후보물질이다</span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">. 2015</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">년 계약금 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">1</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">억</span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">500</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">만달</span></div>
<div class="txt" style="position:absolute; left:38px; top:321px;"><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">러를 비롯하여 총 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">9</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">억</span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">1500</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">만달러에 기술이전 했다</span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">. </span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">다만 한미약품은 이 약물의</span></div>
<div class="txt" style="position:absolute; left:38px; top:337px;"><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">권리가 반환돼도 이미 수령한 계약금 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">1</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">억</span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">500</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">만달러는 반환할 의무가 없다</span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">.</span></div>
<div class="txt" style="position:absolute; left:38px; top:367px;"><span id="f5" style="font-size:12px;vertical-align:baseline;color:rgba(85,146,206,1);">가보지 않은 길을 걷다 만나는 난항이 계속되고 있다</span></div>
<div class="txt" style="position:absolute; left:38px; top:385px;"><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">한미약품은 올해 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">1</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">월 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">Eli Lilly(HM71224), 2018</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">년 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">8</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">월 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">Zai Lab(</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">올리타</span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">), 9</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">월</span></div>
<div class="txt" style="position:absolute; left:38px; top:400px;"><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">Boehringer Ingelheim(</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">올리타</span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">) </span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">등으로부터 기술반환을 통보받은 바 있다</span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">. </span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">올해 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">3</span></div>
<div class="txt" style="position:absolute; left:38px; top:417px;"><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">월에는 파트너사 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">Spectrum</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">이 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">Rolontis</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">의 허가신청을 취하했고 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">2016</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">년 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">12</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">월 사</span></div>
<div class="txt" style="position:absolute; left:38px; top:433px;"><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">노피와의 계약이 일부 수정되는 등 신약개발에 있어 수차례의 난항을 겪었다</span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">. </span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">이</span></div>
<div class="txt" style="position:absolute; left:38px; top:448px;"><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">는 글로벌 신약개발이 얼마나 어려운지를 단편적으로 보여주는 사례다</span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">. </span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">한편 올해</span></div>
<div class="txt" style="position:absolute; left:38px; top:465px;"><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">하반기 예정된 마일스톤으로는 고형암 치료제 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">Oraxol 3</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">상 종료</span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">, </span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">비만</span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">/NASH </span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">치료</span></div>
<div class="txt" style="position:absolute; left:38px; top:481px;"><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">제 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">HM15211</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">과 선천성 고인슐린증 치료제 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">HM15136</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">의 임상 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">1</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">상 종료</span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">, </span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">비소세</span></div>
<div class="txt" style="position:absolute; left:38px; top:496px;"><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">포폐암 치료제 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">Poziotinib</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">의 임상 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">2</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">상 중간결과 발표 등이 있다</span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">. </span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">그러나 이는 개발</span></div>
<div class="txt" style="position:absolute; left:38px; top:513px;"><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">단계가 초기인 만큼 기업가치를 의미있게 끌어올리기에는 한계가 있는 이벤트다</span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">.</span></div>
<div class="txt" style="position:absolute; left:38px; top:543px;"><span id="f5" style="font-size:12px;vertical-align:baseline;color:rgba(85,146,206,1);">우리가 원하는 건 기술반환이 아니라 기술수출</span></div>
<div class="txt" style="position:absolute; left:38px; top:561px;"><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">이번에 반환된 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">HM12525A</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">의 가치 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">7,220</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">억원 차감한 후의 목표주가는 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">44</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">만원으</span></div>
<div class="txt" style="position:absolute; left:38px; top:577px;"><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">로 주가의 상승여력은 제한적이기 때문에 투자의견을 매수에서 중립으로 하향한다</span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">.</span></div>
<div class="txt" style="position:absolute; left:38px; top:592px;"><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">한미약품은 지난해에 이어 올해도 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">2</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">천억원에 가까운 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">R&amp;D</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">비용을 집행할 전망이다</span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">.</span></div>
<div class="txt" style="position:absolute; left:38px; top:609px;"><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">반면 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">2018</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">년 영업현금흐름은 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">260</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">억원에 불과하며 순차입금은 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">5</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">천억원을 상회해</span></div>
<div class="txt" style="position:absolute; left:38px; top:625px;"><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">재무적 부담이 크다</span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">. </span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">이제는 추가적인 기술수출과 같은 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">R&amp;D </span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">결실이 수반되지 않</span></div>
<div class="txt" style="position:absolute; left:38px; top:640px;"><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">는다면 현재의 </span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">valuation</span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">은 정당화가 힘들다</span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">. </span><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">한미약품을 매수하기 위해서는 새로</span></div>
<div class="txt" style="position:absolute; left:38px; top:657px;"><span id="f6" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">운 모멘텀이 절실하다</span><span id="f7" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">.</span></div>
<div class="txt" style="position:absolute; left:412px; top:239px;"><span id="f2" style="font-size:8px;vertical-align:baseline;color:rgba(0,0,0,1);">Stock Data</span></div>
<div class="txt" style="position:absolute; left:412px; top:252px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">KOSPI(7/3)</span></div>
<div class="txt" style="position:absolute; left:542px; top:252px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">2,096</span></div>
<div class="txt" style="position:absolute; left:412px; top:263px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">주가</span><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">(7/3)</span></div>
<div class="txt" style="position:absolute; left:536px; top:263px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">414,500</span></div>
<div class="txt" style="position:absolute; left:412px; top:275px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">시가총액</span><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">(</span><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">십억원</span><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">)</span></div>
<div class="txt" style="position:absolute; left:542px; top:275px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">4,813</span></div>
<div class="txt" style="position:absolute; left:412px; top:286px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">발행주식수</span><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">(</span><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">백만</span><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">)</span></div>
<div class="txt" style="position:absolute; left:551px; top:286px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">12</span></div>
<div class="txt" style="position:absolute; left:412px; top:298px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">52</span><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">주 최고</span><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">/</span><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">최저가</span><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">(</span><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">원</span><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">)</span></div>
<div class="txt" style="position:absolute; left:511px; top:298px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">505,315/372,363</span></div>
<div class="txt" style="position:absolute; left:412px; top:309px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">일평균거래대금</span><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">(6</span><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">개월</span><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">, </span><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">백만원</span><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">)</span></div>
<div class="txt" style="position:absolute; left:539px; top:309px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">13,023</span></div>
<div class="txt" style="position:absolute; left:412px; top:320px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">유동주식비율</span><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">/</span><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">외국인지분율</span><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">(%)</span></div>
<div class="txt" style="position:absolute; left:532px; top:320px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">58.0/15.6</span></div>
<div class="txt" style="position:absolute; left:412px; top:332px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">주요주주</span><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">(%) </span><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">한미사이언스 외 </span><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">3 </span><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">인</span></div>
<div class="txt" style="position:absolute; left:546px; top:332px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">41.4</span></div>
<div class="txt" style="position:absolute; left:462px; top:343px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">국민연금공단</span></div>
<div class="txt" style="position:absolute; left:546px; top:343px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">10.0</span></div>
<div class="txt" style="position:absolute; left:412px; top:365px;"><span id="f5" style="font-size:8px;vertical-align:baseline;color:rgba(0,0,0,1);">주가상승률</span></div>
<div class="txt" style="position:absolute; left:412px; top:389px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">절대주가</span><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">(%)</span></div>
<div class="txt" style="position:absolute; left:412px; top:400px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">KOSPI </span><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">대비</span><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">(%p)</span></div>
<div class="txt" style="position:absolute; left:485px; top:378px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">1</span><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">개월</span></div>
<div class="txt" style="position:absolute; left:491px; top:389px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">1.2</span></div>
<div class="txt" style="position:absolute; left:487px; top:400px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">(0.1)</span></div>
<div class="txt" style="position:absolute; left:514px; top:378px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">6</span><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">개월</span></div>
<div class="txt" style="position:absolute; left:516px; top:389px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">(4.8)</span></div>
<div class="txt" style="position:absolute; left:512px; top:400px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">(10.0)</span></div>
<div class="txt" style="position:absolute; left:539px; top:378px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">12</span><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">개월</span></div>
<div class="txt" style="position:absolute; left:549px; top:389px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">3.9</span></div>
<div class="txt" style="position:absolute; left:546px; top:400px;"><span id="f2" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">11.7</span></div>
<div class="txt" style="position:absolute; left:412px; top:422px;"><span id="f5" style="font-size:8px;vertical-align:baseline;color:rgba(0,0,0,1);">주가추이</span></div>
<div class="txt" style="position:absolute; left:429px; top:440px;"><span id="f9" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(</span><span id="f11" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">천원</span><span id="f9" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">)</span></div>
<div class="txt" style="position:absolute; left:413px; top:445px;"><span id="f9" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">700</span></div>
<div class="txt" style="position:absolute; left:413px; top:460px;"><span id="f9" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">620</span></div>
<div class="txt" style="position:absolute; left:413px; top:475px;"><span id="f9" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">540</span></div>
<div class="txt" style="position:absolute; left:413px; top:490px;"><span id="f9" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">460</span></div>
<div class="txt" style="position:absolute; left:413px; top:505px;"><span id="f9" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">380</span></div>
<div class="txt" style="position:absolute; left:413px; top:520px;"><span id="f9" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">300</span></div>
<div class="txt" style="position:absolute; left:422px; top:527px;"><span id="f9" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">Jul-17</span></div>
<div class="txt" style="position:absolute; left:412px; top:541px;"><span id="f5" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">자료</span><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">: FnGuide</span></div>
<div class="txt" style="position:absolute; left:473px; top:527px;"><span id="f9" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">Jul-18</span></div>
<div class="txt" style="position:absolute; left:524px; top:527px;"><span id="f9" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">Jul-19</span></div>
<div class="txt" style="position:absolute; left:38px; top:769px;"><span id="f5" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">주</span><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">: </span><span id="f5" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">순이익</span><span id="f2" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">, EPS </span><span id="f5" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">등은 지배주주지분 기준</span></div>
<div class="txt" style="position:absolute; left:412px; top:749px;"><span id="f1" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">hg.jin@truefriend.com</span></div>
</body>
</html>
